Localized pharmaceutical manufacturing is attractive for supply resilience, industrial capability and market access. Yet the central question is not whether documents can be delivered to a receiving site. It is whether the receiving organization can repeatedly execute the transferred process within a demonstrated state of control.
1. Treat transfer as a lifecycle project
WHO’s current technology-transfer guideline describes transfer as part of product lifecycle management and expects a science- and risk-based approach, due diligence, gap analysis, trained personnel, knowledge management and documented evidence that the receiving unit can routinely reproduce the transferred product, process or procedure against agreed specifications. ICH Q10 likewise places technology transfer between development and commercial manufacturing within a pharmaceutical quality system. [1] [2]
This changes the project objective. “Send the dossier and train the operators” is an activity list. “Demonstrate that the receiving unit can manufacture and test the product within predefined acceptance criteria, and maintain that control through changes” is an outcome.
2. Complete due diligence before committing the transfer path
A structured gap assessment should compare the sending unit, receiving unit and target-market requirements. At minimum, it should cover:
- product knowledge, critical quality attributes, critical process parameters and the existing control strategy;
- facility, utilities, environmental controls, equipment design, automation and data systems;
- raw materials, components, suppliers, compendial standards and local sourcing constraints;
- analytical methods, reference standards, sample handling, method-transfer requirements and laboratory capacity;
- batch size, hold times, mixing and heat/mass-transfer differences, packaging and logistics;
- regulatory commitments, approved dossier content, variation strategy and validation expectations;
- people, language, training, governance, document control, intellectual property and confidentiality.
The output should not be a generic checklist marked “acceptable.” It should be a risk-ranked plan identifying which gaps can be eliminated, which require studies or engineering work, which require regulatory action and which make the transfer commercially unjustified.
3. Define six connected transfer workstreams
Knowledge and documentation
The transfer package should explain why the process works, not only what steps are performed. Development history, failed approaches, proven ranges, material sensitivities and known failure modes often determine how quickly a receiving team can respond when results move toward an edge of the operating range.
Facility and equipment fit
Equipment with the same nominal function is not automatically equivalent. Geometry, mixing energy, heat transfer, filling path, control logic and sensor locations may change process behavior. Engineering assessments and, where appropriate, development or demonstration batches should resolve the differences.
Analytical transfer
Analytical methods are part of the control strategy. The protocol should specify responsibilities, samples, standards, instruments, training, predefined acceptance criteria, deviations and the statistical treatment of results. A method that cannot be reliably executed at the receiving laboratory can delay release even when manufacturing succeeds.
Materials and supply chain
Source changes can affect processability and product performance. Supplier qualification, specifications, comparability and regulatory implications need to be built into the transfer plan rather than addressed after local procurement begins.
Scale-up and process validation
FDA’s process-validation guidance describes a lifecycle approach linking process design, process qualification and continued process verification. A transfer plan should similarly connect product and process understanding to qualification and ongoing monitoring instead of treating validation as a one-time batch exercise. [3]
Quality and regulatory change
Every transfer decision must be assessed against current approvals and target-market commitments. Changes to site, process, equipment, analytical methods, materials or packaging may require documentation or regulatory action. The technical plan and regulatory plan must therefore use one controlled change record and one agreed evidence map.
4. Add specific controls for sterile and lyophilized products
Sterile projects require additional attention to contamination-control strategy, personnel and material flows, environmental and utility controls, sterilization or aseptic-processing design, container-closure integrity, hold times and intervention risks. For lyophilized products, formulation behavior, freezing and drying steps, loading pattern, equipment capability and cycle reproducibility must be understood at the receiving scale. The exact study package depends on the product, process, regulatory status and receiving-site design; it should never be inferred from a dosage-form label alone.
5. Govern the project with evidence-based stage gates
Target product profile, market, parties and high-risk gaps are understood.
Documents, methods, samples, standards, responsibilities and acceptance criteria are approved.
Facility, equipment, laboratory, materials, people and systems are qualified for planned execution.
Engineering, method-transfer and scale-up evidence meets predefined criteria.
Validation strategy, dossier impact, release path and supply controls are complete.
Continued monitoring, change control, investigations and knowledge ownership are operational.
6. Local capability is the durable output
A successful localization project leaves more than a licensed product. It creates trained teams, controlled knowledge, repeatable methods, capable suppliers, qualified systems and a governance model that can support future products. That is why technical output and capability-building output should both appear in the project charter and acceptance criteria.
Authoritative sources
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.